TrialScientific reports2017

Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study.

Laura Pizzuti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.